# baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus

> **NCT01204593** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 206 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** INSULIN GLARGINE
- **DRUG:** INSULIN GLULISINE

## Key facts

- **NCT ID:** NCT01204593
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2014-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01204593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01204593, "baSal BoluS Therapy in patIenTs With TypE 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01204593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*